News
-
2024-05 13MORE
The latest academic progress – 恩维达® has entered the consensus of gastric cancer surgery for the first time, and the data of advanced biliary tract cancer will be presented in the APASL oral report
With the widespread clinical application of the subcutaneous injection of PD-L1 antibody drug 恩维达® (Envafolimab)in tumor treatment, good news of i...
-
2023-10 30MORE
VOLUNTARY ANNOUNCEMENT APPROVAL FROM FDA TO PROCEED WITH A GLOBAL PHASE III TRIAL FOR TREATMENT OF THE FIRST LINE MISMATCH REPAIR PROFICIENT (pMMR) ADVANCED OR RECURRENT ENDOMETRIAL CANCER
VOLUNTARY ANNOUNCEMENT APPROVAL FROM FDA TO PROCEED WITH A GLOBAL PHASE III TRIAL FOR TREATMENT OF THE FIRST LINE MISMATCH REPAIR PROFICIENT (pMMR) ADVANCED OR RECURRENT ENDOMETRIAL CANCER
-
2022-12 15MORE
3D Medicines Inc. Successfully Listed on the Main Board of HKEX，Stock code：1244.HK
(Hong Kong, December 15 , 2022) A biopharmaceutical company in China for the development and commercialization of next-generation tumor immunotherapy drugs - 3D Medicines Inc. (“ 3D Medicines” or the “Company”, Stock Code: 1244.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange”) today.
-
2022-10 10MORE
3D Medicines Announces Subject Dosed in Phase I Clinical Trial of 3D189, a Potential WT1-Targeting Heteroclitic Cancer Vaccine，in Patients with Hematological Malignancies
Beijing, China October 8, 2022- 3D Medicines Inc. announced today that the subject has been dosed in the Phase I clinical trial for 3D189 (also known as galinpepimut-S, or GPS), which is the first clinical trial in China for this product to assess the safety and immunogenicity of 3D189 in patients with hematological malignancies. The first dosing of the first participant was completed. 3D Medicines holds the exclusive license from SELLAS to develop, manufacture and commercialize 3D189 in China, Hong Kong, Macau and Taiwan region for all therapeutic and other diagnostic uses.
-
2022-04 18MORE
3D Medicines Announces that the IND of Batiraxcept+Envafolimab/Lenvatinib for Advanced Solid Tumor Cancer was Approved by NMPA
Beijing, China April 18, 2022 - 3D Medicines Inc. (3D Medicines) announces that the multi-center, open-label phase Ib/II clinical trial of Batiraxcept (3D229) in combination with envafolimab or lenvatinib in patients with advanced solid tumor was approved by China’s National Medical Products Administration (NMPA).
-
2022-04 06MORE
3D Medicines Inc. Announces that the IND for Phase 1 Clinical Trial to Evaluate 3D189 (Galinpepimut-S), a peptide cancer vaccine, was approved by NMPA
Beijing，April 6，2022 - 3D Medicines Inc. (the “Company”), today announced that an IND application to initiate the first clinical trial in China for 3D189, also known as SELLAS’s galinpepimut-s (“GPS”), has been approved by China’s National Medical Products Administration (“NMPA”) to evaluate safety and immunogenicity of 3D189 in Chinese patients with hematological malignancies.
